10-Q: Immunome Reports Third Quarter 2024 Financial Results and Provides Business Update

Immunome, Inc. reported a net loss of $47.1 million for the third quarter of 2024, driven by increased research and development expenses, while highlighting progress in its clinical and preclinical programs.

Summary

• Immunome, Inc. reported a net loss of $47.1 million for the three months ended September 30, 2024, compared to a net loss of $4.3 million for the same period in 2023.
• The company's operating expenses totaled $53.4 million for the quarter, with significant increases in research and development costs.
• Collaboration revenue decreased to $2.9 million for the quarter, down from $3.6 million in the prior year.
• For the nine months ended September 30, 2024, Immunome's net loss was $212.7 million, compared to $14.2 million for the same period in 2023.
• The company's cash and cash equivalents stood at $155.6 million, with marketable securities of $84.6 million as of September 30, 2024.
• Immunome expects its current cash, cash equivalents, and marketable securities to fund operations for at least 12 months from the filing date of the report.
• The company is advancing a pipeline that includes AL102, a Phase 3 clinical asset, and two preclinical assets, IM-1021 and IM-3050.
• The company anticipates submitting an IND for IM-1021 and IM-3050 in the first quarter of 2025.
• Immunome completed the acquisition of Ayala Pharmaceuticals' AL101 and AL102 programs in March 2024, and acquired certain antibody-related assets from Atreca in May 2024.
• The company also completed the acquisition of Morphimmune in October 2023.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While the company has a strong cash position and is progressing its pipeline, the significant increase in net loss and operating expenses raises concerns. The company is also reliant on future capital raises.

Positives

• Immunome has a strong cash position of $155.6 million and $84.6 million in marketable securities, which is expected to fund operations for at least 12 months.
• The company is progressing its clinical asset, AL102, through a Phase 3 trial, with topline data expected in the second half of 2025.
• Immunome is advancing two preclinical assets, IM-1021 and IM-3050, with IND submissions planned for the first quarter of 2025.
• The company has successfully completed several strategic acquisitions, including Ayala Pharmaceuticals and Atreca, expanding its pipeline and capabilities.

Negatives

• The company experienced a significant increase in net loss, from $4.3 million in Q3 2023 to $47.1 million in Q3 2024.
• Research and development expenses have increased substantially, reaching $37.2 million in Q3 2024.
• Collaboration revenue decreased to $2.9 million in Q3 2024, down from $3.6 million in Q3 2023.
• The company has an accumulated deficit of $435.5 million as of September 30, 2024.

Risks

• The company has a history of losses and expects to continue incurring significant losses for the foreseeable future.
• Immunome has a limited operating history, which makes it difficult to evaluate its drug development capabilities and predict future performance.
• The company has not yet demonstrated successful completion of clinical development, submitted a New Drug Application, or obtained FDA approval for marketing.
• There is no guarantee that the collaboration with AbbVie will result in successful discovery and validation of targets.
• Clinical trials are expensive, time-consuming, and difficult to design and implement.
• The company may face challenges in recruiting patients for clinical trials.
• The market price of the company's common stock is expected to be volatile.
• The company may need to raise additional capital through equity offerings, debt financings, collaborations, strategic alliances and licensing arrangements to achieve its longer-term business objectives.
• The company is subject to stringent and evolving U.S. and foreign laws, regulations, and rules, contractual obligations, industry standards, policies and other obligations related to data privacy and security.
• The company is subject to U.S. and foreign anti-corruption and anti-money laundering laws with respect to its operations.
• The company may be unable to successfully scale manufacturing in sufficient quality and quantity, which would delay or prevent it from completing its development and commercialization efforts.
• The company is subject to a variety of evolving threats, including social-engineering attacks, malicious code, malware, denial-of-service attacks, ransomware attacks, supply-chain attacks, and other similar threats.
• The company's current laboratory operations are concentrated in one location, and it may be adversely affected by natural or other disasters.
• It is difficult and costly to protect the company's intellectual property and proprietary technologies.
• The company may be subject to claims by third parties that it or its employees or consultants have wrongfully used or disclosed their alleged trade secrets or other proprietary information.

Future Outlook

Immunome expects its current cash, cash equivalents, and marketable securities to fund operations for at least 12 months from the filing date of the report. The company anticipates submitting an IND for IM-1021 and IM-3050 in the first quarter of 2025 and expects to publish topline data for RINGSIDE Part B in the second half of 2025.

Management Comments

• The company believes that the pursuit of novel or underexplored targets will be central to the next generation of transformative therapies.
• The company's goal is to establish a broad pipeline of preclinical and clinical assets and develop these assets into approved products for commercialization.
• The company pairs business development activity with significant investment in its internal discovery programs.

Industry Context

The announcement reflects the ongoing trend in the biotechnology industry of companies focusing on targeted oncology therapies and the development of novel drug candidates. The company's focus on ADCs and radioligand therapies aligns with current industry trends in cancer treatment.

Comparison to Industry Standards

• The increase in R&D spending is typical for a biotech company in the clinical stage, as they invest heavily in advancing their pipeline.
• The net loss is consistent with other early-stage biotech companies that are still in the development phase and have not yet generated product revenue.
• The company's cash position is relatively strong compared to other companies of similar size, providing a runway for continued operations.
• The company's focus on novel targets and mechanisms of action is in line with the industry's push for innovative cancer therapies.
• The company's acquisition strategy is similar to other biotech companies that seek to expand their pipeline through strategic transactions.

Stakeholder Impact

• Shareholders may be concerned about the increased net loss and the need for potential future capital raises.
• Employees may be affected by the company's financial performance and any potential changes in operations.
• Customers and suppliers may be impacted by the company's ability to develop and commercialize its products.
• Creditors may be concerned about the company's ability to repay its debts.

Next Steps

• The company plans to submit INDs for IM-1021 and IM-3050 in the first quarter of 2025.
• The company expects to publish topline data for RINGSIDE Part B in the second half of 2025.
• The company will continue to invest in discovery efforts to expand its pipeline.

Key Dates

Keywords

Oncology, Biotechnology, Targeted Therapy, Antibody-Drug Conjugate, Radioligand Therapy, Clinical Trials, Drug Development, Gamma Secretase Inhibitor, ROR1, FAP